3 Potential Biotech Buyout Targets In 2024

seekingalpha03-19

Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows.Deal volume should remain strong in 2024 as large pharma concerns have ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420278427?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1471917167/image_1471917167.jpg","is_english":true,"pubTime":"2024-03-19 22:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2420278427","market":"sg","top_or_hot":-1,"title":"3 Potential Biotech Buyout Targets In 2024","media":"seekingalpha","content":"<div>\n<p>Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows.Deal volume should remain strong in 2024 as large pharma concerns have ...</p>\n\n<a href=\"https://seekingalpha.com/article/4679123-3-potential-biotech-buyout-targets-in-2024\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Potential Biotech Buyout Targets In 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Potential Biotech Buyout Targets In 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-19 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4679123-3-potential-biotech-buyout-targets-in-2024><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows.Deal volume should remain strong in 2024 as large pharma concerns have ...</p>\n\n<a href=\"https://seekingalpha.com/article/4679123-3-potential-biotech-buyout-targets-in-2024\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://seekingalpha.com/article/4679123-3-potential-biotech-buyout-targets-in-2024","article_id":"2420278427","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1471917167/image_1471917167.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420278427","pubTimestamp":1710857779,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows.Deal volume should remain strong in 2024 as large pharma concerns have larg","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LLY":"礼来","BK7095":"多种金属与采矿","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK7104":"黄金","XBI":"SPDR S&P Biotech ETF","IMGN":"ImmunoGen","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","ACAD":"阿卡迪亚","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","KRTX":"Karuna Therapeutics","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","AZN":"阿斯利康","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","CYTK":"Cytokinetics","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","PFE.AU":"PANTERA MINERALS LTD","JNJ":"强生","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","NVS":"诺华","SG9999002232.USD":"Allianz Global High Payout USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","SG9999002224.SGD":"Allianz Global High Payout SGD","AMGN":"安进","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4007":"制药","BK4566":"资本集团","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","PFE":"辉瑞","CERE":"Cerevel Therapeutics Holdings, Inc.","NVO.AU":"NOVO RESOURCES CORP-CDI","VKTX":"Viking Therapeutics, Inc."},"translate_title":"2024年3个潜在生物技术收购目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"XBI":1,"VKTX":1,"PFE.AU":1,"PFE":1,"NVS":1,"NVO.AU":1,"NVO":1,"LLY":1,"KRTX":1,"JNJ":1,"ACAD":1,"AZN":1,"CYTK":1,"IMGN":1,"CERE":1},"content_text":"Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows.Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations and desire entry into new markets.Three logical buyout targets in the biotech/biopharma space in 2024 are highlighted below.   Ralf HahnThe biotech sector saw a surge of M&A activity at the end of 2023. Major deals to acquire ImmunoGen, Inc. (IMGN), Cerevel Therapeutics Holdings, Inc. (CERE) and Karuna Therapeutics, Inc. (KRTX) all took place in the final five weeks of last year. Each purchase contained a substantial buyout premium as well for shareholders. The uptick in deal volume was one of key drivers of the 50% rally that took place from the SPDR® S&P Biotech ETF (XBI) off its late October lows. That rally has ebbed in recent weeks as has new deal flow. Seeking Alpha However, 2024 should be a solid year for acquisitions in the biotech/biopharma space. Big drug makers have large amounts of cash sitting on their balance sheets. Blockbuster drugs like Lynparza from AstraZeneca PLC (AZN) and Xarelto from Janssen Pharmaceuticals, a division of Johnson & Johnson (JNJ) face key patent expirations. Other large drug concerns like Pfizer (PFE) have seen Covid vaccine sales fall dramatically from their peaks. Oncology has been and will likely remain a key area for M&A activity. However, today we will highlight three non-oncology focused biotech/biopharma concerns that would make logical and speculated buyout targets. Let's start with Cytokinetics, Incorporated (CYTK) whose CEO stated last week the company was perfectly good remaining a standalone entity. There has already been speculation that either Amgen (AMGN) or Novartis (NVS) could be possible acquirers, but the board was reportedly holding out for $130 to $145 a share, which seems a bridge too far at the moment. UBS stated in late January that $105 a share was a more reasonable buyout price. The company's CFO resigned in early February which clouded the picture around a potential takeout. Seeking Alpha This takeout chatter was triggered when the company posted approval-worthy results from a Phase 3 study evaluating its lead drug candidate aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in late December. All of this news flow has resulted in a wild ride for shareholders over the past three months (see above).   March 2023 Company Presentation   March 2023 Company Presentation HCM impacts just under 300,000 diagnosed in the United States. An estimated 400,000-800,000 additional patients are believed to remain undiagnosed. This is the target market aficamten is aiming for. HCM is currently addressed with cardio myosin inhibitors, non-vasodilating beta blockers, calcium and sodium channel blockers, but approximately one-third of oHCM patients do not improve, which can lead to more invasive procedures.   March 2023 Company Presentation A dozen analyst firms including Goldman Sachs, Jefferies, Barclays and Piper Sandler have reiterated/assigned Buy/Outperform ratings on the stock since Phase 3 study data was posted near the close of last year. Price targets range from $78 to $122 a share with the median price target in the high $90s. Given the size of the target market and a market cap of just less than $7 billion, CYTK would be one of least surprising acquisitions that could occur in 2024. Seeking Alpha ACADIA Pharmaceuticals Inc. (ACAD) has had the opposite journey in recent trading action compared to Cytokinetics, and for good reason. The company announced last week that its key asset pimavanserin (known by the brand name Nuplazid), that was being evaluated for the treatment of negative symptoms of schizophrenia in a Phase 3 study, did not meet the trial's primary endpoint. Nuplazid is the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The compound did nearly $550 million in sales last year and is seeing mid-single digits sales growth. The compound has seen some patent litigation, which Acadia had a key legal victory around a few months ago. Management has stated it sees its 'composition of matter' patents holding, which will ward off any generic competition to 2030. In addition to Nuplazid, the company's drug trofinetide (brand name Daybue) became the only FDA treatment for the rare disease Rett Syndrome in the spring of last year. The treatment has gained significant initial traction in the market and management has guided it sees between $370 million to $420 million in net product sales for the drug in FY2024. The company should file a marketing application for Daybue in Canada soon and one in Europe early in 2025. Daybue's success is driving the company towards profitability. ACADIA lost 37 cents a share in FY2023 on just over $725 million in sales. The current analyst firm consensus sees the company having profits of 67 cents a share in FY2024 as revenues rise to nearly $970 million.   February Company Presentation Besides Nuplazid and Daybue, the company has a couple of other compounds in development. However, its only late-stage effort is targeting hyperphagia for Prader-Willi Syndrome patients and is currently being evaluated in an ongoing Phase 3 study. ACADIA also commenced a Phase 2 study evaluating ACP-204 for the treatment of Alzheimer’s disease psychosis in the fourth quarter.   February Company Presentation With the overall market for Nuplazid now well-defined and a successful launch of Daybue, ACADIA seems a logical buyout target. The stock has a market cap of just a tad over $3 billion and Acadia should end FY2024 with a cash pile of between $585 million to $655 million according to company guidance. ACADIA Pharmaceuticals seems a good pickup for a larger CNS focused concern with an existing sales force. That would allow the acquirer to slash SG&A costs (just over $400 million in FY2023) drastically and make a buyout in the mid to high $20s quite accretive to the acquiring company. Seeking Alpha We will end with Viking Therapeutics (VKTX), a stock that has a recent trajectory very similar to Cytokinetics in 2024. Viking is one of several smaller firms targeting the large, growing and potentially massive GLP-1 weight loss market that is currently dominated by entrants from drug giants Eli Lilly (LLY) and Novo Nordisk (NVO). In late February, Viking's entrant VK2735, once-weekly, subcutaneously delivered dual agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors posted very strong results in a mid-stage study. The company smartly used the spike in the stock to raise an additional $550 million of funding via a secondary offering. These proceeds extended the company's cash runway to 2027. The GLP-1 drug class are predicted to be the biggest selling category within the pharma market by the of this year and reach $100 billion in annual sales by 2029. Results from an earlier stage trial for an oral version of VK2735 should also be out shortly. Jefferies recently speculated this compound could have $12 billion potential peak sales potential. Viking also has a pipeline candidate targeting NASH, another huge potential market. Some additional data from a promising mid-stage study for that compound 'VK2809' will be out before the close of the first half of this year. February 2024 Company Presentation With a market cap of just under $7 billion, Viking would make an intriguing acquisition for a large drug company wanting to enter the burgeoning GLP-1 space and this also give the acquirer a promising NASH asset as well. Since VK2735 trial results posted, ten analyst firms including Jefferies, Oppenheimer and BTIG have reissued/assigned Buy/Outperform ratings on VKTX. Price targets proffered range from $90 to $120 a share.  And those are three biotech/biopharma companies that should be on a list of logical names that could be acquired in 2024.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420278427"}